{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:05:52Z","timestamp":1794330352903,"version":"4.9.0"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.pharmthera.2023.108519","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:48:36Z","timestamp":1692820116000},"page":"108519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Lactate acidosis and simultaneous recruitment of TGF-\u03b2 leads to alter plasticity of hypoxic cancer cells in tumor microenvironment"],"prefix":"10.1016","volume":"250","author":[{"given":"Saumya","family":"Rastogi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank Shekher","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep Kumar","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Kaithwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugato","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velayutham","family":"Ravichandiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhadeep","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakhveer","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb9030","article-title":"Transforming growth factor-\u03b21 as a common target molecule for development of cardiovascular diseases, renal insufficiency and metabolic syndrome. In Cardiology","volume":"1","author":"Aihara","year":"2011","journal-title":"Research and Practice"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0005","series-title":"Cancers","first-page":"1","article-title":"TGF-\u03b2 in cancer: Metabolic driver of the tolerogenic crosstalk in the tumor microenvironment","volume":"vol. 13, Issue 3","author":"Angioni","year":"2021"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108519_bb9035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2012.05.001","article-title":"Transforming growth factor (TGF)-\u03b2 expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging","volume":"135","author":"Arjaans","year":"2012","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0010","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1080315","article-title":"Homeobox B9 promotes the progression of hepatocellular carcinoma via TGF- \u03b2 1\/Smad and ERK1\/2 signaling pathways","volume":"2022","author":"Bai","year":"2022","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0015","series-title":"Frontiers in Molecular Biosciences","article-title":"The post-translational modifications of Smurf2 in TGF-\u03b2 signaling","volume":"Vol. 7","author":"Bai","year":"2020"},{"issue":"19","key":"10.1016\/j.pharmthera.2023.108519_bb0020","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1016\/j.febslet.2012.07.027","article-title":"SARA is dispensable for functional TGF-\u03b2 signaling","volume":"586","author":"Bakkebo","year":"2012","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0025","article-title":"Pilot study of combination gemogenovatucel-T (vigil) and durvalumab in women with relapsed BRCA-wt triple-negative breast or ovarian cancer","volume":"16","author":"Barve","year":"2022","journal-title":"Clinical Medicine Insights: Oncology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0030","series-title":"Immunity","first-page":"924","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"vol. 50, Issue 4","author":"Batlle","year":"2019"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10946-y","article-title":"Regulation of tumor angiogenesis and mesenchymal\u2013endothelial transition by p38\u03b1 through TGF-\u03b2 and JNK signaling","volume":"10","author":"Batlle","year":"2019","journal-title":"Nature Communications"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108519_bb0040","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.4049\/jimmunol.181.8.5194","article-title":"Cutting edge: autocrine TGF-\u03b2 sustains default tolerogenesis by IDO-competent dendritic cells","volume":"181","author":"Belladonna","year":"2008","journal-title":"The Journal of Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb9095","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.celrep.2014.08.056","article-title":"Fatty acid uptake and lipid storage induced by HIF-1\u03b1 contribute to cell growth and survival after hypoxia-reoxygenation","volume":"9","author":"Bensaad","year":"2014","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0045","doi-asserted-by":"crossref","DOI":"10.1091\/mbc.12.1.27","article-title":"Transforming growth factor-1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism","volume":"12","author":"Bhowmick","year":"2001","journal-title":"Molecular Biology of the Cell"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0050","series-title":"Pharmacology and therapeutics","article-title":"Lactate\/GPR81 signaling and proton motive force in cancer: Role in angiogenesis, immune escape, nutrition, and Warburg phenomenon","volume":"Vol. 206","author":"Brown","year":"2020"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0055","series-title":"Pharmacology and therapeutics","article-title":"The roles of TGF-\u03b2 and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors","volume":"Vol. 240","author":"Bu","year":"2022"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0060","series-title":"International journal of molecular sciences","article-title":"Metabolic pathways of thewarburg effect in health and disease: Perspectives of choice, chain or chance","volume":"Vol. 18, Issue 12","author":"Burns","year":"2017"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0065","article-title":"TGF-\u03b2 enhances immunosuppression of myeloid-derived suppressor cells to induce transplant immune tolerance through affecting Arg-1 expression","volume":"13","author":"Cao","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108519_bb0070","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022111","article-title":"Structural basis of intracellular TGF-\u03b2 signaling: Receptors and smads","volume":"8","author":"Chaikuad","year":"2016","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"38","key":"10.1016\/j.pharmthera.2023.108519_bb0075","doi-asserted-by":"crossref","first-page":"26038","DOI":"10.1074\/jbc.M114.564120","article-title":"Excessive hyaluronan production promotes acquisition of cancer stem cell signatures through the coordinated regulation of twist and the transforming growth factor \u03b2 (TGF-\u03b2)-snail signaling axis","volume":"289","author":"Chanmee","year":"2014","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0080","series-title":"IUBMB life","first-page":"929","article-title":"The tale of transforming growth factor-beta (TGF\u03b2) signaling: A soign\u00e9 enigma","volume":"vol. 61, Issue 10","author":"Chaudhury","year":"2009"},{"key":"10.1016\/j.pharmthera.2023.108519_bb9060","series-title":"Frontiers in Immunology","article-title":"The Love-Hate Relationship Between TGF-\u03b2 Signaling and the Immune System During Development and Tumorigenesis","volume":"Vol. 13","author":"Chen","year":"2022"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0085","series-title":"Cell research","first-page":"58","article-title":"Endocytic regulation of TGF-\u03b2 signaling","volume":"vol. 19, Issue 1","author":"Chen","year":"2009"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108519_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126532","article-title":"TGF-\u03b21 up-regulates connective tissue growth factor expression in human granulosa cells through Smad and ERK1\/2 signaling pathways","volume":"10","author":"Cheng","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1864-y","article-title":"Breast cancer metastasis suppressor 1 (BRMS1) attenuates TGF-\u03b21-induced breast cancer cell aggressiveness through downregulating HIF-1a\u03b1 expression","volume":"15","author":"Cho","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-14262-3","article-title":"TGF\u03b22-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells","volume":"11","author":"Corbet","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0105","series-title":"Nature reviews cancer","first-page":"577","article-title":"Tumour acidosis: From the passenger to the driver\u2019s seat","volume":"vol. 17, Issue 10","author":"Corbet","year":"2017"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108519_bb0110","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cmet.2016.07.003","article-title":"Acidosis drives the reprogramming of fatty acid metabolism in cancer cells through changes in mitochondrial and histone acetylation","volume":"24","author":"Corbet","year":"2016","journal-title":"Cell Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb9050","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6010007","article-title":"Stromal modulators of TGF-\u03b2 in cancer","volume":"6","author":"Costanza","year":"2017","journal-title":"Journal of Clinical Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108519_bb9070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.matbio.2012.11.016","article-title":"Breast tumor and stromal cell responses to TGF-\u03b2 and hypoxia in matrix deposition","volume":"32","author":"Curran","year":"2013","journal-title":"Matrix Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb9040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2003.10.004","article-title":"The transforming growth factor-\u03b2 superfamily of receptors","volume":"15","author":"De Caestecker","year":"2004","journal-title":"Cytokine & growth factor reviews"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108519_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063777","article-title":"Intratumor hypoxia promotes immune tolerance by inducing regulatory T cells via TGF-\u03b21 in gastric cancer","volume":"8","author":"Deng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0120","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.31570","article-title":"Efficacy and safety of luspatercept in the treatment of \u03b2-thalassemia: A systematic review","author":"Dighriri","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0125","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aav3334","article-title":"Tumor-derived TGF-\u03b2 inhibits mitochondrial respiration to suppress IFN-\u03b3 production by human CD4 + T cells","volume":"12","author":"Dimeloe","year":"2019","journal-title":"Science Signaling"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108519_bb9075","doi-asserted-by":"crossref","DOI":"10.3390\/cells8070727","article-title":"Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis","volume":"8","author":"Doyle","year":"2019","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108519_bb9010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006896","article-title":"Hypoxia and TGF-\u03b2 drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment","volume":"4","author":"Dunn","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0130","series-title":"Signal transduction and targeted therapy","article-title":"Molecular principles of metastasis: A hallmark of cancer revisited","volume":"Vol. 5, Issue 1","author":"Fares","year":"2020"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108519_bb9100","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ccell.2020.08.015","article-title":"Cholesterol Pathway Inhibition Induces TGF-\u03b2 Signaling to Promote Basal Differentiation in Pancreatic Cancer","volume":"38","author":"Gabitova-Cornell","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo0987","article-title":"PKM2 promotes pulmonary fibrosis by stabilizing TGF-\u03b21 receptor I and enhancing TGF-\u03b21 signaling","volume":"8","author":"Gao","year":"2022","journal-title":"Science Advances"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108519_bb0140","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1593\/neo.11528","article-title":"Type III TGF-\u03b2 receptor enhances colon cancer cell migration and anchorage-independent growth","volume":"13","author":"Gatza","year":"2011","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108519_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059918","article-title":"TGF-Beta suppresses VEGFA-mediated angiogenesis in colon cancer metastasis","volume":"8","author":"Geng","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb0150","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910681","article-title":"Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGF \u03b2","volume":"12","author":"Germann","year":"2020","journal-title":"EMBO Molecular Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108519_bb9025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbadis.2008.01.006","article-title":"Role of transforming growth factor-\u03b2 superfamily signaling pathways in human disease","volume":"1782","author":"Gordon","year":"2008","journal-title":"In Biochimica et Biophysica Acta - Molecular Basis of Disease"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108519_bb0155","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cellsig.2011.01.022","article-title":"SNX25 regulates TGF-\u03b2 signaling by enhancing the receptor degradation","volume":"23","author":"Hao","year":"2011","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01903","article-title":"The production of pro-angiogenic VEGF-A isoforms by hypoxic human NK cells is independent of their TGF-\u03b2-mediated conversion to an ILC1-like phenotype","volume":"11","author":"Hawke","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0165","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.biopha.2018.02.121","article-title":"Sauchinone prevents TGF-\u03b2-induced EMT and metastasis in gastric cancer cells","volume":"101","author":"He","year":"2018","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0170","series-title":"Drug design, development and therapy","first-page":"4479","article-title":"Clinical development of galunisertib (Ly2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"Vol. 9","author":"Herbertz","year":"2015"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108519_bb9065","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022103","article-title":"Structural biology and evolution of the TGF-\u03b2 family","volume":"8","author":"Hinck","year":"2016","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0175","doi-asserted-by":"crossref","first-page":"S911","DOI":"10.1016\/j.annonc.2020.08.1957","article-title":"1451P comparative response evaluation of cisplatin-capecitabine with cisplatin-5-fluorouracil in advanced gastric carcinoma: A quasi-experimental study","volume":"31","author":"Hoque","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0180","series-title":"Biomedicine and pharmacotherapy","article-title":"Recent progress in TGF-\u03b2 inhibitors for cancer therapy","volume":"Vol. 134","author":"Huang","year":"2021"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb0185","doi-asserted-by":"crossref","DOI":"10.1186\/2045-3701-2-9","article-title":"Regulation of TGF-\u03b2 receptor activity","volume":"2","author":"Huang","year":"2012","journal-title":"Cell & Bioscience"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0190","author":"Huang"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108519_bb0195","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3727\/096368912X657954","article-title":"Hypoxia-induced secretion of TGF-b1 in mesenchymal stem cell promotes breast cancer cell progression","volume":"22","author":"Hung","year":"2013","journal-title":"Cell Transplantation"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108519_bb0200","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1349-7006.2008.00925.x","article-title":"Regulation of TGF-\u03b2 family signaling by E3 ubiquitin ligases","volume":"99","author":"Inoue","year":"2008","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0205","series-title":"International journal of molecular sciences","article-title":"Transforming growth factor-\u03b2 signaling pathway in colorectal cancer and its tumor microenvironment","volume":"vol. 20, Issue 23","author":"Itatani","year":"2019"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108519_bb0210","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ceb.2007.02.015","article-title":"Negative regulation of TGF-\u03b2 receptor\/Smad signal transduction","volume":"19","author":"Itoh","year":"2007","journal-title":"Current Opinion in Cell Biology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/srep14733","article-title":"USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination","volume":"5","author":"Iyengar","year":"2015","journal-title":"Scientific Reports"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108519_bb0220","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/sj.onc.1207412","article-title":"Regulation of the TGF\u03b2 signalling pathway by ubiquitin-mediated degradation","volume":"23","author":"Izzi","year":"2004","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108519_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biology9070143","article-title":"A new TGF-\u03b21 inhibitor, CTI-82, antagonizes epithelial\u2013mesenchymal transition through inhibition of phospho-SMAD2\/3 and phospho-ERK","volume":"9","author":"Jeong","year":"2020","journal-title":"Biology"},{"issue":"30","key":"10.1016\/j.pharmthera.2023.108519_bb9130","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1038\/onc.2014.321","article-title":"Metabolic reprogramming during TGF\u03b21-induced epithelial-to-mesenchymal transition","volume":"34","author":"Jiang","year":"2015","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108519_bb0230","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1172\/JCI125375","article-title":"TGF-\u03b2 signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond syndrome","volume":"129","author":"Joyce","year":"2019","journal-title":"Journal of Clinical Investigation"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108519_bb9125","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1096\/fj.201701187R","article-title":"Fatty acid synthase is required for profibrotic TGF-b signaling","volume":"32","author":"Jung","year":"2018","journal-title":"FASEB Journal"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108519_bb9105","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.chembiol.2009.07.007","article-title":"A Small Molecule That Blocks Fat Synthesis By Inhibiting the Activation of SREBP","volume":"16","author":"Kamisuki","year":"2009","journal-title":"Chemistry and Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108519_bb9005","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040569","article-title":"Oncogenic and tumor suppressive components of the cell cycle in breast cancer progression and prognosis","volume":"13","author":"Kashyap","year":"2021","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108519_bb0235","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1681\/ASN.2006070754","article-title":"Role of the Akt\/FoxO3a pathway in TGF-\u03b21-mediated mesangial cell dysfunction: A novel mechanism related to diabetic kidney disease","volume":"17","author":"Kato","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0240","series-title":"Molecular cell","article-title":"* Program in molecular biology and cancer Samuel Lunenfeld Research Institute Mount Sinai Hospital pathway","volume":"vol. 6","author":"Kavsak","year":"2023"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0245","series-title":"Cell","first-page":"52","article-title":"Matrix metalloproteinases: Regulators of the tumor microenvironment","volume":"vol. 141, Issue 1","author":"Kessenbrock","year":"2010"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bcp.2019.03.031","article-title":"Therapeutic potential of pharmacological TGF-\u03b2 signaling pathway inhibitors in the pathogenesis of breast cancer","volume":"164","author":"Khoshakhlagh","year":"2019","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0255","series-title":"Frontiers in oncology","article-title":"Smurfs in protein homeostasis, signaling, and cancer","volume":"Vol. 8, Issue AUG","author":"Koganti","year":"2018"},{"key":"10.1016\/j.pharmthera.2023.108519_bb9090","doi-asserted-by":"crossref","unstructured":"Koundouros, N., & Poulogiannis, G. (2020). Reprogramming of fatty acid metabolism in cancer. In British Journal of Cancer (Vol. 122, Issue 1, pp. 4\u201322). Springer Nature. https:\/\/doi.org\/10.1038\/s41416-019-0650-z.","DOI":"10.1038\/s41416-019-0650-z"},{"issue":"26","key":"10.1016\/j.pharmthera.2023.108519_bb0260","doi-asserted-by":"crossref","first-page":"22480","DOI":"10.18632\/oncotarget.4310","article-title":"Modulation of cerebral endothelial cell function by TGF-\u03b2 in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition","volume":"6","author":"Krishnan","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0265","author":"Kubiczkova"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0270","article-title":"Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint","volume":"83","author":"Kumar Verma","year":"2022","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108519_bb9020","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/jid.2014.20","article-title":"TGF-\u03b2-induced (TGFBI) protein in melanoma: A signature of high metastatic potential","volume":"134","author":"Lauden","year":"2014","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0275","series-title":"Frontiers in immunology","article-title":"Impairment of NKG2D-mediated tumor immunity by TGF-\u03b2","volume":"Vol. 10","author":"Lazarova","year":"2019"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108519_bb0280","doi-asserted-by":"crossref","first-page":"213","DOI":"10.15430\/JCP.2020.25.4.213","article-title":"Recent advances in the development of TGF-\u03b2 signaling inhibitors for anticancer therapy","volume":"25","author":"Lee","year":"2020","journal-title":"Journal of Cancer Prevention"},{"issue":"20","key":"10.1016\/j.pharmthera.2023.108519_bb0285","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1002\/cam4.4259","article-title":"Reducing tumor invasiveness by ramucirumab and TGF-\u03b2 receptor kinase inhibitor in a diffuse-type gastric cancer patient-derived cell model","volume":"10","author":"Lee","year":"2021","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0290","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.omto.2019.08.001","article-title":"Exosomal leucine-rich-Alpha2-glycoprotein 1 derived from non-small-cell lung cancer cells promotes angiogenesis via TGF-\u03b2 signal pathway","volume":"14","author":"Li","year":"2019","journal-title":"Molecular Therapy - Oncolytics"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0295","article-title":"Conditional ablation of TGF-\u03b2 signaling inhibits tumor progression and invasion in an induced mouse bladder cancer model","volume":"6","author":"Liang","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0300","series-title":"Nature Cancer","first-page":"911","article-title":"Cancer vaccines: The next immunotherapy frontier","volume":"vol. 3, Issue 8","author":"Lin","year":"2022"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0305","series-title":"Journal for immunotherapy of cancer","article-title":"Dual targeting of TGF-\u03b2 and PD-L1 via a bifunctional anti-PD-L1\/TGF-\u03b2RII agent: Status of preclinical and clinical advances","volume":"vol. 8, Issue 1","author":"Lind","year":"2020"},{"issue":"7832","key":"10.1016\/j.pharmthera.2023.108519_bb0310","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2836-1","article-title":"TGF-\u03b2 suppresses type 2 immunity to cancer","volume":"587","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0315","series-title":"Signal transduction and targeted therapy","article-title":"Targeting TGF\u03b2 signal transduction for cancer therapy","volume":"Vol. 6, Issue 1","author":"Liu","year":"2021"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0320","series-title":"Cell research","first-page":"21","article-title":"Regulating the stability of TGF\u03b2 receptors and Smads","volume":"vol. 19, Issue 1","author":"L\u00f6nn","year":"2009"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108519_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213482","article-title":"LRRC33 is a novel binding and potential regulating protein of TGF-\u03b21 function in human acute myeloid leukemia cells","volume":"14","author":"Ma","year":"2019","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.pharmthera.2023.108519_bb0330","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1080\/15384101.2019.1642069","article-title":"Interactions between TGF-\u03b2 type I receptor and hypoxia-inducible factor-\u03b1 mediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinoma","volume":"18","author":"Mallikarjuna","year":"2019","journal-title":"Cell Cycle"},{"issue":"7693","key":"10.1016\/j.pharmthera.2023.108519_bb0335","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108519_bb9045","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1016\/j.febslet.2006.04.033","article-title":"The logic of TGF\u03b2 signaling","volume":"580","author":"Massagu\u00e9","year":"2006","journal-title":"In FEBS Letters"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2023.108519_bb0340","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-2478(02)00023-8","article-title":"Mechanisms of TGF-\u03b2 signaling in regulation of cell growth and differentiation","volume":"82","author":"Moustakas","year":"2002","journal-title":"Immunology Letters"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108519_bb9110","doi-asserted-by":"crossref","DOI":"10.3390\/membranes11070479","article-title":"Polyunsaturated fatty acids mediated regulation of membrane biochemistry and tumor cell membrane integrity","volume":"11","author":"Mukerjee","year":"2021","journal-title":"Membranes"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0345","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"83","author":"Muz","year":"2015","journal-title":"Hypoxia"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0350","series-title":"International journal of molecular sciences","article-title":"HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance","volume":"vol. 20, Issue 2","author":"Nagao","year":"2019"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0355","doi-asserted-by":"crossref","DOI":"10.1038\/srep09650","article-title":"HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGF\u03b2-signaling in hypoxic microenvironment","volume":"5","author":"Nagpal","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0360","doi-asserted-by":"crossref","DOI":"10.1038\/srep09650","article-title":"HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGF\u03b2-signaling in hypoxic microenvironment","volume":"5","author":"Nagpal","year":"2015","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108519_bb0365","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ygyno.2016.09.018","article-title":"Phase II study of Vigil\u00ae DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer","volume":"143","author":"Oh","year":"2016","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb0370","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5972-y","article-title":"VEGF-C induced by TGF- \u03b21 signaling in gastric cancer enhances tumor-induced lymphangiogenesis","volume":"19","author":"Pak","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108519_bb0375","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3892\/ijo.2015.2816","article-title":"Role of TGF\u03b2 in regulation of the tumor microenvironment and drug delivery (review)","volume":"46","author":"Papageorgis","year":"2015","journal-title":"International Journal of Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108519_bb0380","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pharmthera.2012.10.002","article-title":"Overlapping activities of TGF-\u03b2 and Hedgehog signaling in cancer: Therapeutic targets for cancer treatment","volume":"137","author":"Perrot","year":"2013","journal-title":"Pharmacology and Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb0385","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-022-03112-6","article-title":"Fortilin interacts with TGF-\u03b21 and prevents TGF-\u03b2 receptor activation","volume":"5","author":"Pinkaew","year":"2022","journal-title":"Communications Biology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0390","series-title":"Mediators of inflammation","article-title":"Transforming growth factor beta family: Insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications","volume":"vol. 2015","author":"Poniatowski","year":"2015"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108519_bb0395","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt369","article-title":"TGF-\u03b2: Duality of function between tumor prevention and carcinogenesis. In","volume":"106","author":"Principe","year":"2014","journal-title":"Journal of the National Cancer Institute"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108519_bb9154","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T cells by \u03b3c family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nature Reviews Immunology"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108519_bb0400","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S1470-2045(20)30533-7","article-title":"Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III\/IV ovarian cancer (VITAL): A randomised, double-blind, placebo-controlled, phase 2b trial","volume":"21","author":"Rocconi","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2023.108519_bb0405","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41417-021-00317-5","article-title":"Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer","volume":"29","author":"Rocconi","year":"2022","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0410","series-title":"Frontiers in cell and developmental biology","article-title":"Extracellular vesicles and transforming growth factor \u03b2 signaling in cancer","volume":"Vol. 10","author":"Rodrigues-Junior","year":"2022"},{"issue":"849938","key":"10.1016\/j.pharmthera.2023.108519_bb0415","first-page":"1","article-title":"Extracellular vesicles and transforming growth factor \u03b2 signaling in cancer","volume":"10","author":"Rodrigues-Junior","year":"2022","journal-title":"Frontiers in Cell and Development Biology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0420","author":"Roy"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0425","series-title":"TGF\u03b21I1 suppressed cell migration and invasion in colorectal cancer by inhibiting the TGF-\u03b2 pathway and EMT progress","author":"Ruan","year":"2020"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108519_bb0430","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.bbagen.2012.08.008","article-title":"TGF-\u03b2 family signaling in stem cells","volume":"1830","author":"Sakaki-Yumoto","year":"2013","journal-title":"Biochimica et Biophysica Acta - General Subjects"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108519_bb0435","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022236","article-title":"Regulation of the immune response by TGF-\u03b2: From conception to autoimmunity and infection","volume":"9","author":"Sanjabi","year":"2017","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01536","article-title":"Is lactate an oncometabolite? Evidence supporting a role for lactate in the regulation of transcriptional activity of cancer-related genes in MCF7 breast cancer cells","volume":"9","author":"San-Mill\u00e1n","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108519_bb0445","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.RES.0000191538.76771.66","article-title":"Nitric oxide regulates transforming growth factor-\u03b2 signaling in endothelial cells","volume":"97","author":"Saura","year":"2005","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0450","series-title":"International journal of molecular sciences","article-title":"Natural killer cells\u2014An epigenetic perspective of development and regulation","volume":"Vol. 17, Issue 3","author":"Schenk","year":"2016"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108519_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078935","article-title":"Lactate-modulated induction of THBS-1 activates transforming growth factor (TGF)-beta2 and migration of glioma cells in vitro","volume":"8","author":"Seliger","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0460","series-title":"Journal of hematology and oncology","article-title":"TGF-\u03b2 signaling in the tumor metabolic microenvironment and targeted therapies","volume":"vol. 15, Issue 1","author":"Shi","year":"2022"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0465","series-title":"Cell","article-title":"Review mechanisms of TGF-signaling from cell membrane to the nucleus have been observed in both TGF-family receptors and the Smad proteins. The TGF-type II receptor is inacti-vated by mutation in most human gastrointestinal can","volume":"vol. 113","author":"Shi","year":"2003"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb0470","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jb\/mvs136","article-title":"Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. In","volume":"153","author":"Shibuya","year":"2013","journal-title":"Journal of Biochemistry"},{"issue":"6 June","key":"10.1016\/j.pharmthera.2023.108519_bb0475","article-title":"TGF-\u03b2 inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model","volume":"16","author":"Siewe","year":"2021","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108519_bb9000","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.drudis.2018.05.016","article-title":"Prolyl hydroxylase 2: a promising target to inhibit hypoxia-induced cellular metabolism in cancer cells","volume":"23","author":"Singh","year":"2018","journal-title":"Drug discovery today"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0480","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1034205","article-title":"Hypoxia induced lactate acidosis modulates tumor microenvironment and lipid reprogramming to sustain the cancer cell survival","volume":"13","author":"Singh","year":"2023","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.736910","article-title":"Repurposing combination therapy of voacamine with vincristine for downregulation of hypoxia-inducible factor-1\u03b1\/fatty acid synthase co-axis and prolyl hydroxylase-2 activation in ER+ mammary neoplasia","volume":"9","author":"Singh","year":"2021","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"17","key":"10.1016\/j.pharmthera.2023.108519_bb0490","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1158\/1078-0432.CCR-11-3224","article-title":"Molecular pathways: Targeting the TGF-\u03b2 pathway for cancer therapy","volume":"18","author":"Smith","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108519_bb0495","first-page":"3930","article-title":"Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice","volume":"118","author":"Sonveaux","year":"2008","journal-title":"Journal of Clinical Investigation"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108519_bb9135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115543","article-title":"Epithelial\u2013mesenchymal transition (Emt) induced by tgf-\u03b2 in hepatocellular carcinoma cells reprograms lipid metabolism","volume":"22","author":"Soukupova","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108519_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102390","article-title":"TGF-\u03b2 signaling initiated in dendritic cells instructs suppressive effects on Th17 differentiation at the site of neuroinflammation","volume":"9","author":"Speck","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0505","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ebiom.2019.02.025","article-title":"Oxidized ATM-mediated glycolysis enhancement in breast cancer-associated fibroblasts contributes to tumor invasion through lactate as metabolic coupling","volume":"41","author":"Sun","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb0510","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12931-019-0988-z","article-title":"BAMBI regulates macrophages inducing the differentiation of Treg through the TGF-\u03b2 pathway in chronic obstructive pulmonary disease","volume":"20","author":"Sun","year":"2019","journal-title":"Respiratory Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108519_bb0515","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/jcb.25496","article-title":"TGF-\u03b2 signaling in Cancer","volume":"117","author":"Syed","year":"2016","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0520","series-title":"Journal of biological chemistry","first-page":"12559","article-title":"Targeting all transforming growth factor-b isoforms with an Fc chimeric receptor impairs tumor growth and angiogenesis of oral squamous cell cancer","volume":"vol. 295, Issue 36","author":"Takahashi","year":"2020"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0525","series-title":"International journal of molecular sciences","article-title":"The clinical potential of oligonucleotide therapeutics against pancreatic cancer","volume":"Vol. 20, Issue 13","author":"Takakura","year":"2019"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108519_bb9085","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1074\/jbc.M116.773085","article-title":"Transforming growth factor-\u03b2 (TGF-\u03b2) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway","volume":"292","author":"Tang","year":"2017","journal-title":"Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108519_bb0530","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"issue":"23","key":"10.1016\/j.pharmthera.2023.108519_bb0535","article-title":"Transforming growth factor beta type 1 (TGF-and hypoxia-inducible factor 1 (HIF-1)) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells","volume":"2020","author":"Teo","year":"2020","journal-title":"AGING"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108519_bb0540","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-\u03b2 directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0545","series-title":"International journal of molecular sciences","article-title":"TGF-\u03b2 signaling in cellular senescence and aging-related pathology","volume":"Vol. 20, Issue 20","author":"Tominaga","year":"2019"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108519_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051284","article-title":"Acidosis-induced TGF-\u03b22 production promotes lipid droplet formation in dendritic cells and alters their potential to support anti-mesothelioma T cell response","volume":"12","author":"Trempolec","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0555","series-title":"Biomolecules","article-title":"TGF-\u0392 signaling","volume":"Vol. 10, Issue 3","author":"Tzavlaki","year":"2020"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0560","series-title":"TGF-\u03b21 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis","author":"Varricchio","year":"2021"},{"issue":"6 June","key":"10.1016\/j.pharmthera.2023.108519_bb0565","article-title":"Adenosine\/TGF\u03b2 axis in regulation of mammary fibroblast functions","volume":"16","author":"Vasiukov","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108519_bb0570","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ekir.2017.03.011","article-title":"A phase 2, double-blind, placebo-controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis","volume":"2","author":"Vincenti","year":"2017","journal-title":"Kidney International Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb0575","article-title":"TGF-\u03b2 participates choroid neovascularization through Smad2\/3-VEGF\/TNF-\u03b1 signaling in mice with laser-induced wet age-related macular degeneration","volume":"7","author":"Wang","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0580","series-title":"Frontiers in oncology","article-title":"Acetyl-CoA carboxylases and diseases","volume":"Vol. 12","author":"Wang","year":"2022"},{"issue":"17","key":"10.1016\/j.pharmthera.2023.108519_bb9015","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.272.17.11444","article-title":"Biosynthesis of the Type I and Type II TGF-Receptors IMPLICATIONS FOR COMPLEX FORMATION*. In","volume":"272","author":"Wells","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108519_bb0585","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/1091581821998945","article-title":"Nonclinical development of SRK-181: An anti-latent TGF\u03b21 monoclonal antibody for the treatment of locally advanced or metastatic solid tumors","volume":"40","author":"Welsh","year":"2021","journal-title":"International Journal of Toxicology"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0590","doi-asserted-by":"crossref","DOI":"10.1038\/srep43800","article-title":"Dynamics of cancerous tissue correlates with invasiveness","volume":"7","author":"West","year":"2017","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb9055","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis. In Nature Communications","volume":"11","author":"Winkler","year":"2020","journal-title":"Nature Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108519_bb0595","first-page":"3693","article-title":"TGF-\u03b21-induced cell migration in pancreatic carcinoma cells is RAC1 and NOX4-dependent and requires RAC1 and NOX4-dependent activation of p38 MAPK","volume":"38","author":"Witte","year":"2017","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2023.108519_bb9115","doi-asserted-by":"crossref","unstructured":"Yang, L., Zhang, F., Wang, X., Tsai, Y., Chuang, K.-H., Keng, P.C., Lee, S.O., & Chen, Y. (n.d.). A FASN-TGF-\u03b21-FASN regulatory loop contributes to high EMT\/ metastatic potential of cisplatin-resistant non-small cell lung cancer. 7(34). http:\/\/www.impactjournals.com\/oncotarget.","DOI":"10.18632\/oncotarget.10837"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108519_bb0600","article-title":"Dehydropeptidase 1 promotes metastasis through regulation of E-cadherin expression in colon cancer","volume":"7","author":"Yoon Park","year":"2023","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0605","series-title":"Neoplasma","first-page":"1","article-title":"The contribution of TGF-\u03b2 in epithelial\u2013mesenchymal transition (EMT): Down-regulation of E-cadherin via snail","volume":"vol. 62, Issue 1","author":"Yu","year":"2015"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb9080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.blre.2012.12.002","article-title":"Extracellular vesicles in physiological and pathological conditions","volume":"27","author":"Yuana","year":"2013","journal-title":"Blood Reviews"},{"key":"10.1016\/j.pharmthera.2023.108519_bb9120","doi-asserted-by":"crossref","unstructured":"Yue Loo, S., Ping Toh, L., Haowei Xie, W., Pathak, E., Tan, W., Ma, S., Yin Lee, M., Shatishwaran, S., Zhen Zhen Yeo, J., Yuan, J., Ying Ho, Y., Kai Lay Peh, E., Muniandy, M., Torta, F., Chan, J., Tan, T.J., Sim, Y., Tan, V., Tan, B., \u2026 Leong Tam, W. (2021). Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer. In Sci. Adv. 7. https:\/\/www.science.org.","DOI":"10.1126\/sciadv.abh2443"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108519_bb0610","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2002-02-0629","article-title":"Cellular response to hypoxia involves signaling via Smad proteins","volume":"101","author":"Zhang","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2023.108519_bb0615","series-title":"Biophysics and computational biology","article-title":"Zuo contributed new reagents\/analytic tools","volume":"vol. 106","author":"Zhang","year":"2009"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108519_bb0620","article-title":"Interleukin 37 promotes angiogenesis through TGF-\u03b2 signaling","volume":"7","author":"Zhao","year":"2017","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108519_bb0625","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/1878-0261.12162","article-title":"TGF-\u03b2 transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK\/Sp1 signaling pathways","volume":"12","author":"Zhao","year":"2018","journal-title":"Molecular Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108519_bb0630","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/lt.21966","article-title":"Inhibition of transforming growth factor-\u03b2\/Smad signaling improves regeneration of small-for-size rat liver grafts","volume":"16","author":"Zhong","year":"2010","journal-title":"Liver Transplantation"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:35:06Z","timestamp":1759012506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823001833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":155,"alternative-id":["S0163725823001833"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108519","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lactate acidosis and simultaneous recruitment of TGF-\u03b2 leads to alter plasticity of hypoxic cancer cells in tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108519"}}